去乙酰化酶SIRTs在帕金森病中的研究进展

doi:10.16352/j.issn.1001-6325.2024.11.1603

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (11): 1603-1607.doi: 10.16352/j.issn.1001-6325.2024.11.1603

去乙酰化酶SIRTs在帕金森病中的研究进展

方雪¹, 石瑾², 李海宁¹, 杨娟^1*

1.宁夏医科大学总医院神经内科,宁夏银川 750004;
2.贺兰县人民医院神经内科,宁夏银川 750200

收稿日期:2023-10-19 修回日期:2024-04-03 出版日期:2024-11-05 发布日期:2024-10-31
通讯作者: ^*yangjuan7@163.com
基金资助:
宁夏自然科学基金(2022AAC03561);宁夏回族自治区重点研发计划(2022BEG03130);宁夏医科大学校级项目(XZ2020010)

Progress of deacetylase SIRTs in pathogenesis of Parkinson's disease

FANG Xue¹, SHI Jin², LI Haining¹, YANG Juan^1*

1. Department of Neurology, General Hospital of Ningxia Medical University, Yinchuan 750004;
2. Department of Neurology, Helan County People's Hospital, Yinchuan 750200, China

Received:2023-10-19 Revised:2024-04-03 Online:2024-11-05 Published:2024-10-31
Contact: ^*yangjuan7@163.com

摘要/Abstract

摘要： Sirtuins(SIRTs)是一类依赖于NAD⁺的去乙酰化酶,在神经退行性疾病中,特别是在帕金森病(PD)中备受关注。Sirtuins通过调控细胞内的代谢、应激反应和DNA修复等多种生物学过程,对细胞存活和凋亡具有重要作用。在PD的发病机制中,Sirtuins发挥关键作用,与线粒体功能、氧化应激及神经元凋亡等病理生理过程紧密相关。激活Sirtuins能够减轻PD动物模型的运动障碍和神经元损伤,同时调节α-突触核蛋白(α-Syn)的聚集和清除,这是PD的病理特征之一。因此,调节Sirtuins可能成为治疗PD的潜在策略之一。

关键词: 帕金森病, 去乙酰化酶Sirtuins, α-突触核蛋白

Abstract: Sirtuins(SIRTs), a group of NAD⁺ dependent deacetylases, have attracted considerable attention in the field of neuro-degenerative diseases, especially Parkinson's disease (PD). They have critical impacts on cell survival and death through modulation of various biological processes, such as intracellular metabolism, stress response and DNA repair. In the pathogenesis of PD, Sirtuins play a crucial role and associated with pathophysiological processes such as mitochondrial function, oxidative stress, and neuronal apoptosis. Activation of Sirtuins alleviates dyskinesia and neuronal damage in animal models of PD and also regulates the aggregation and clearance of α-synuclein, a pathological feature of the disease. Therefore, the modulation of Sirtuins is a potential strategy for treating PD.

Key words: Parkinson's disease, deacetylase Sirtuins, α-synuclein

中图分类号:

方雪, 石瑾, 李海宁, 杨娟. 去乙酰化酶SIRTs在帕金森病中的研究进展[J]. 基础医学与临床, 2024, 44(11): 1603-1607.

FANG Xue, SHI Jin, LI Haining, YANG Juan. Progress of deacetylase SIRTs in pathogenesis of Parkinson's disease[J]. Basic & Clinical Medicine, 2024, 44(11): 1603-1607.

参考文献

[1] Chojdak-Lukasiewicz J, Bizon A, Waliszewska-Prosol M, et al. Role of Sirtuins in physiology and diseases of the central nervous system[J]. Biomedicines, 2022, 10.doi:10.3390/biomedicines10102434.
[2] Yeong KY, Berdigaliyev N, Chang Y. Sirtuins and their implications in neurodegenerative diseases from a drug discovery perspective[J]. ACS Chem Neurosci, 2020, 11:4073-91.doi:10.1021/acschemneuro.0c00696.
[3] Khan H, Tiwari P, Kaur A, et al. Sirtuin acetylation and deacetylation: a complex paradigm in neurodegenerative disease[J]. Mol Neurobiol, 2021, 58:3903-17.doi:10.1007/s12035-021-02387-w.
[4] Lei Y, Wang J, Wang D, et al. SIRT1 in forebrain excitatory neurons produces sexually dimorphic effects on depression-related behaviors and modulates neuronal excitability and synaptic transmission in the medial prefrontal cortex[J]. Mol Psychiatry, 2020, 25:1094-111.doi:10.1038/s41380-019-0352-1.
[5] Singh V, Ubaid S. Role of silent information regulator 1 (SIRT1) in regulating oxidative stress and inflammation[J]. Inflammation, 2020, 43:1589-1598.doi:10.1007/s10753-020-01242-9.
[6] Huang Q, Su H, Qi B, et al. A SIRT1 activator, ginsenoside Rc, promotes energy metabolism in cardiomyocytes and neurons[J]. J Am Chem Soc, 2021, 143:1416-1427.doi:10.1021/jacs.0c10836.
[7] Li X, Feng Y, Wang XX, et al. The critical role of SIRT1 in Parkinson's disease: mechanism and therapeutic considerations[J]. Aging Dis, 2020, 11:1608-1622.doi:10.14336/AD.2020.0216.
[8] Jiao F, Gong Z. The beneficial roles of SIRT1 in neuroinflammation-related diseases[J]. Oxid Med Cell Longev, 2020, 2020:6782872.doi:10.1155/2020/6782872.
[9] Haque ME, Akther M, Azam S, et al. Targeting alpha-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease[J]. Br J Pharmacol, 2022, 179:23-45.doi:10.1111/bph.15684.
[10] Dong Z, Wang Y, Hao C, et al. Sanghuangporus sanghuang extract extended the lifespan and healthspan of caenorhabditis elegans via DAF-16/SIR-2.1[J]. Front Pharmacol, 2023, 14:1136897.doi:10.3389/fphar.2023.1136897.
[11] Kaitsuka T, Matsushita M, Matsushita N. Regulation of hypoxic signaling and oxidative stress via the microRNA-SIRT2 axis and its relationship with aging-related diseases[J]. Cells, 2021, 10.doi:10.3390/cells10123316.
[12] Yang Q, Zhou Y, Sun Y, et al. Will Sirtuins be promising therapeutic targets for TBI and associated neurodegenerative diseases?[J]. Front Neurosci, 2020, 14:791.doi:10.3389/fnins.2020.00791.
[13] Saramowicz K, Siwecka N, Galita G, et al. Alpha-synuclein contribution to neuronal and Glial damage in Parkinson's disease[J]. Int J Mol Sci, 2023, 25.doi:10.3390/ijms25010360.
[14] Akbulut KG, Keskin-Aktan A, Abgarmi SA, et al. The role of SIRT2 inhibition on the aging process of brain in male rats[J]. Aging Brain, 2023, 4:100087.doi:10.1016/j.nbas.2023.100087.
[15] He L, Wang J, Yang Y, et al. Mitochondrial Sirtuins in Parkinson's Disease[J]. Neurochem Res, 2022, 47:1491-1502.doi:10.1007/s11064-022-03560-w.
[16] He M, Chiang HH, Luo H, et al. An acetylation switch of the NLRP3 inflammasome regulates aging-associated chronic inflammation and insulin resistance[J]. Cell Metab, 2020, 31:580-91 e5.doi:10.1016/j.cmet.2020.01.009.
[17] Nie H, Hong Y, Lu X, et al. SIRT2 mediates oxidative stress-induced apoptosis of differentiated PC12 cells[J]. Neuroreport, 2014, 25:838-842.doi:10.1097/WNR.0000000000000192.
[18] Garmendia-Berges M, Sola-Sevilla N, Mera-Delgado M, et al. Age-associated changes of Sirtuin 2 expression in CNS and the periphery[J]. Biology (Basel), 2023, 12.doi:10.3390/biology12121476.
[19] Hu J, Kan T, Hu X. Sirt3 regulates mitophagy level to promote diabetic corneal epithelial wound healing[J]. Exp Eye Res, 2019, 181:223-231.doi:10.1016/j.exer.2019.02.011.
[20] Zhou TY, Wu YG, Zhang YZ, et al. SIRT3 retards intervertebral disc degeneration by anti-oxidative stress by activating the SIRT3/FOXO3/SOD2 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23:9180-9188.doi:10.26355/eurrev_201911_19408.
[21] Shefa U, Jeong NY, Song IO, et al. Mitophagy links oxidative stress conditions and neurodegenerative diseases[J]. Neural Regen Res, 2019, 14:749-756.doi:10.4103/1673-5374.249218.
[22] Zhang S, Ma Y, Feng J. Neuroprotective mechanisms of epsilon-viniferin in a rotenone-induced cell model of Parkinson's disease: significance of SIRT3-mediated FOXO3 deacetylation[J]. Neural Regen Res, 2020, 15:2143-2153.doi:10.4103/1673-5374.282264.
[23] Wang R, Sun H, Wang G, et al. Imbalance of lysine acetylation contributes to the pathogenesis of Parkinson's disease[J]. Int J Mol Sci, 2020, 21.doi:10.3390/ijms21197182.
[24] Luo H, Peng C, Xu X, et al. The protective effects of mogroside V against neuronal damages by attenuating mitochondrial dysfunction via upregulating Sirtuin3[J]. Mol Neurobiol, 2022, 59:2068-2084.doi:10.1007/s12035-021-02689-z.
[25] Zeng R, Wang X, Zhou Q, et al. Icariin protects rotenone-induced neurotoxicity through induction of SIRT3[J]. Toxicol Appl Pharmacol, 2019, 379:114639.doi:10.1016/j.taap.2019.114639.

去乙酰化酶SIRTs在帕金森病中的研究进展

Progress of deacetylase SIRTs in pathogenesis of Parkinson's disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于曼殊, 赵晓敏, 邱明月, 刘春冉, 那日苏. 牙源性干细胞治疗帕金森病的研究进展[J]. 基础医学与临床, 2024, 44(9): 1298-1302.
[2]	任鹏, 陈雅丽, 张娴文. 帕金森病嗅觉障碍的研究进展[J]. 基础医学与临床, 2023, 43(6): 994-997.
[3]	岳静静, 伍超, 高歌, 鲁玲玲. α-突触核蛋白/A53T突变体损伤SH-SY5Y细胞的MAM并导致线粒体结构异常及自噬[J]. 基础医学与临床, 2023, 43(2): 219-224.
[4]	沈露茜, 徐学静, 叶逸繁, 陈卓, 陈兰, 申钰琪, 李红智. 导入酵母NDI1基因减少鱼藤酮诱导的分化型帕金森病细胞模型的损伤[J]. 基础医学与临床, 2023, 43(10): 1491-1497.
[5]	左赋兴, 苑青, 蔡洪庆, 韩睿钦, 万经海. 新型微量注射装置在建立帕金森病模型小鼠中的应用[J]. 基础医学与临床, 2022, 42(7): 1031-1034.
[6]	吴长宝, 郝延磊. STAT3与帕金森病发病机制的研究进展[J]. 基础医学与临床, 2022, 42(12): 1935-1938.
[7]	马利芳, 梁建庆, 何建成, 孙雪, 梁鹏. 谷氨酸转运体在帕金森病发病机制中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1813-1817.
[8]	邢靖松, 克甜甜, 张琳, 梁东, 张桐, 高尚锋. Spinophilin在神经系统疾病中的研究进展[J]. 基础医学与临床, 2021, 41(10): 1507-1509.
[9]	于琳琳李正迁韩登阳杨宁倪诚史成梅郭向阳. APP/PS1双转基因AD小鼠术后认知功能紊乱及其机制[J]. 基础医学与临床, 2019, 39(4): 478-482.
[10]	翟骁段国礼沈下贤陈晓. α-突触核蛋白在帕金森病中的作用[J]. 基础医学与临床, 2012, 32(12): 1481-1483.
[11]	赵长振. 阿米洛利对PC12细胞的保护作用及其对分子伴侣自噬通路的影响[J]. 基础医学与临床, 2011, 31(10): 1124-1128.
[12]	吴晶晶陈彪. 小胶质细胞通过IL-1加重帕金森病进展[J]. 基础医学与临床, 2010, 30(10): 1100-1104.
[13]	梁彩霞徐云智赵春礼郑德宇段德义 . HLA A表达沉默和酪氨酸羟化酶过表达人成纤维细胞脑内移植治疗帕金森病大鼠模型[J]. 基础医学与临床, 2009, 29(7): 697-703.
[14]	刘琦段春礼吴波范春香张韬赵焕英赵春礼杨慧. α-突触核蛋白磷酸化参与小鼠多巴胺能神经元的保护作用[J]. 基础医学与临床, 2009, 29(6): 561-565.
[15]	张莉王彦永崔冬生顾平王铭维. LPS致大鼠黑质多巴胺能神经元及血清TNF-α变化的研究[J]. 基础医学与临床, 2008, 28(7): 747-751.